Global Interferon Biosimilar Insights Report 2020: Focus on MAB 2, ReliBeta, PF-08, Interferon beta-1b biosimilar, DA-3051, Cinno Vex, ReciGen, Bioferon, Inmutag, Alpheon, BCD-033, Megavex
September 30, 2020 02:54 ET
|
Research and Markets
Dublin, Sept. 30, 2020 (GLOBE NEWSWIRE) -- The "Interferon - Biosimilar Insight, 2020" report has been added to ResearchAndMarkets.com's offering. Interferon - Biosimilar Insight, 2020 report...
BetterLife Scales up Manufacturing of AP-003 (Interferon Alpha 2b) to Prepare for Clinical Trials
September 17, 2020 07:30 ET
|
BetterLife Pharma
VANCOUVER, Sept. 17, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company, today announced it has...
BetterLife Pharma Announces Dr. Eleanor Fish to Retain Role as Key Scientific Advisor Following Invitation to Join Government COVID-19 Task Force
September 02, 2020 07:30 ET
|
BetterLife Pharma
Vancouver, Sept. 02, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT), an emerging biotechnology company, today announced that...
BetterLife Pharma Receives Approval from Altum Pharmaceuticals Inc. Shareholders to Complete Merger
July 30, 2020 07:30 ET
|
BetterLife Pharma
Vancouver, July 30, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT), an emerging biotechnology company with proprietary...
BetterLife CEO Discusses Synairgen’s Interferon Breakthrough Treatment
July 28, 2020 08:00 ET
|
BetterLife Pharma
New York City, July 28, 2020 (GLOBE NEWSWIRE) -- The Chief Executive Officer for BetterLife Pharma Inc. (OTCQB:BETRF) (CSE:BETR), an emerging biotechnology company currently preparing a potential...
BetterLife CEO Discusses Merger, Planned Interferon Treatment Trials and Potential Subsequent FDA Emergency Use Authorization
July 23, 2020 08:00 ET
|
BetterLife Pharma
New York City, July 23, 2020 (GLOBE NEWSWIRE) -- The Chief Executive Officer for BetterLife Pharma Inc. (OTCQB:BETRD) (CSE:BETR), an emerging biotechnology company currently preparing its own...
Interferon Treatment Trial 'a Major Breakthrough' Against the Pandemic
July 21, 2020 08:00 ET
|
BetterLife Pharma
NEW YORK CITY, July 21, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. ("BetterLife" or the "Company") (OTCQB:BETRD) (CSE:BETR) has been a strong advocate and defender of using interferons as...
BetterLife (OTCQB:BETRD) Launches Website Emphasizing 3 Potentially Ground Breaking Treatments
July 14, 2020 08:00 ET
|
BetterLife Pharma
New York City, July 14, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE:BETR) (OTCQB:BETRD) (FRA: BLife Therapeutics BLife TherapeuticsNPAT) indicated the...
BetterLife Pharma (OTCB:BETRD) CEO Discusses Using Interferons to Defeat ‘Truly Evil Virus’
July 06, 2020 07:30 ET
|
BetterLife Pharma
New York City, July 06, 2020 (GLOBE NEWSWIRE) -- The CEO of BetterLife Pharma (OTCQB:BETRD) (CSE: BETR) (FRANKFURT: NPAT), an emerging clinical stage pharmaceutical development company, recently...
Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding
September 23, 2019 03:00 ET
|
Biogen Inc.
Positive opinion is supported by data from more than 1,000 real-world pregnancy outcomes Data indicate no increased risk of major congenital anomalies after exposure to interferon beta before...